Video wird geladen...

Video konnte nicht geladen werden

Zur Startseite

Today, we are launching the first publicly available AI Scientist, via the FutureHouse Platform. Our AI Scientist agents can perform a wide variety of scientific tasks better than humans. By chaining them together, we've already started to discover new biology really fast. With the platform, we are bringing these...

725,776 Aufrufe • vor 1 Jahr •via X (Twitter)

10 Kommentare

Profilbild von ksminnovation
ksminnovationvor 1 Jahr

AI is transforming healthcare! A KSM-led study shows AI can detect Celiac disease 4 years earlier @TalPatalon @MedPredict

Profilbild von FutureHouse
FutureHousevor 1 Jahr

Check out our platform at and read more at our blog post below!

Profilbild von John Hemming
John Hemmingvor 1 Jahr

What have you actually discovered?

Profilbild von Sam Rodriques
Sam Rodriquesvor 1 Jahr

Coming soon!!

Profilbild von Josh Hone
Josh Honevor 1 Jahr

@AdamMarblestone Love the naming; especially owl == “who”

Profilbild von Jason Kelly
Jason Kellyvor 1 Jahr

Congrats Sam! 🎉

Profilbild von Deep Prasad (yug-cybera) 🏴‍☠️
Deep Prasad (yug-cybera) 🏴‍☠️vor 1 Jahr

Is there a paper or preprint we can read up on this new biology?

Profilbild von Sam Rodriques
Sam Rodriquesvor 1 Jahr

Stay tuned 🙂

Profilbild von Jasmine Dhaliwal
Jasmine Dhaliwalvor 1 Jahr

What an amazing team! 🥳

Profilbild von Piyush
Piyushvor 1 Jahr

Fascinating stuff! This is going to be a game changer!

Ähnliche Videos

Today, we’re announcing Kosmos, our newest AI Scientist, available to use now. Users estimate Kosmos does 6 months of work in a single day. One run can read 1,500 papers and write 42,000 lines of code. At least 79% of its findings are reproducible. Kosmos has made 7 discoveries so far, which we are releasing today, in areas ranging from neuroscience to material science and clinical genetics, in collaboration with our academic beta testers. Three of these discoveries reproduced unpublished findings; four are net new, validated contributions to the scientific literature. AI-accelerated science is here. Our core innovation in Kosmos is the use of a structured, continuously-updated world model. As described in our technical report, Kosmos’ world model allows it to process orders of magnitude more information than could fit into the context of even the longest-context language models, allowing it to synthesize more information and pursue coherent goals over longer time horizons than Robin or any of our other prior agents. In this respect, we believe Kosmos is the most compute-intensive language agent released so far in any field, and by far the most capable AI Scientist available today. The use of a persistent world model also enables single Kosmos trajectories to produce highly complex outputs that require multiple significant logical leaps. As with all of our systems, Kosmos is designed with transparency and verifiability in mind: every conclusion in a Kosmos report can be traced through our platform to the specific lines of code or the specific passages in the scientific literature that inspired it, ensuring that Kosmos’ findings are fully auditable at all times. We are also using this opportunity to announce the launch of Edison Scientific, a new commercial spinout of FutureHouse, which will be focused on commercializing our agents and applying them to automate scientific research in drug discovery and beyond. Edison will be taking over management of the FutureHouse platform, where you can access Kosmos alongside our Literature, Molecules, and Precedent agents (previously Crow, Phoenix, and Owl). Edison will continue to offer free tier usage for casual users and academics, while also offering higher rate limits and additional features for users who need them. You can read more about this spinout on our blog, below. A few important notes if you’re going to try Kosmos. Firstly, Kosmos is different from many other AI tools you might have played with, including our other agents. It is more similar to a Deep Research tool than it is to a chatbot: it takes some time to figure out how to prompt it effectively, and we have tried to include guidelines on this to help (see below). It costs $200/run right now (200 credits per run, and $1/credit), with some free tier usage for academics. This is heavily discounted; people who sign up for Founding Subscriptions now can lock in the $1/credit price indefinitely, but the price ultimately will probably be higher. Again, this is less chatbot and more research tool, something you run on high-value targets as needed. Some caveats are also warranted. Firstly, we find that 80% of Kosmos findings are reproducible, which also means 20% are not -- some things it says will be wrong. Also, Kosmos certainly does produce outputs that are the equivalent to several months of human labor, but it also often goes down rabbit holes or chases statistically significant yet scientifically irrelevant findings. We often run Kosmos multiple times on the same objective in order to sample the various research avenues it can take. There are still a bunch of rough edges on the UI and such, which we are working on. Finally, we are aware that the 6 month figure is much greater than estimates by other AI labs, like METR, about the length of tasks that AI Agents can currently perform. You can read discussion about this in our blog post. Huge congratulations to our team that put this together, led by Ludovico Mitchener and Michaela Hinks: Angela Yiu, Benjamin Chang, Sid Narayanan, Edwin Melville-Green, Albert Bou, Arvis Sulovari, Oz Wassie, Jon Laurent. A particular shout out to Michael Skarlinski and his team that rebuilt the platform for this launch, especially Andy Cai Andy Cai, Richard Magness, Remo Storni, Tyler Nadolski Tyler Nadolski, Mayk Caldas Mayk Caldas, Sam Cox Sam Cox and more. This work would not have been possible without significant contributions from academic collaborators Mathieu Bourdenx, Eric Landsness, Dániel Barabási, Nicky Evans, Tonio Buonassisi, Bruna Gomes, Shriya Reddy, Martha Foiani, and Randall Bateman. We also want to thank our numerous supporters, especially Eric Schmidt, who has been a tremendous ally. We will have more to say about our supporters soon!

Sam Rodriques

732,619 Aufrufe • vor 9 Monaten

Today, we’re announcing the first major discovery made by our AI Scientist with the lab in the loop: a promising new treatment for dry AMD, a major cause of blindness. Our agents generated the hypotheses, designed the experiments, analyzed the data, iterated, even made figures for the paper. The resulting manuscript is a first-of-a-kind in the natural sciences, in which everything that needed to be done to write the paper was done by AI agents, apart from actually conducting the physical experiments in the lab and writing the final manuscript. We are also introducing Robin, the first multi-agent system that fully automates the in-silico components of scientific discovery, which made this discovery. This is the first time that we are aware of that hypothesis generation, experimentation, and data analysis have been joined up in closed loop, and is the beginning of a massive acceleration in the pace of scientific discovery that will be driven by these agents. We will be open-sourcing the code and data next week. Robin is a multi-agent system that uses Crow, Falcon, and Finch, the agents on our platform, to generate novel hypotheses, plan experiments, and analyze data. We asked Robin to find a new treatment for dry age-related macular degeneration. Robin considered the disease mechanisms associated with dry AMD, proposed a specific experimental assay that could be used to evaluate hypotheses in the wet lab, and proposed specific molecules we could test in that assay. We tested the molecules and gave it the resulting data, which it analyzed before proposing more experiments. In the end, it identified Ripasudil, a Rho Kinase inhibitor (ROCK inhibitor) that is approved in Japan for several other diseases, which seems very promising as potential treatment for dry AMD. It also identified specific molecular mechanisms that might underlie the effects of Ripasudil in RPE cells, from an RNA sequencing experiment it proposed. To be clear, no one has proposed using ROCK inhibitors to treat dry AMD in the literature before, as far as we can find, and I think it would have been very difficult for us to come up with this hypothesis without the agents. We have also run the proposed treatment by several experts in AMD, who confirm that it is interesting and novel. Moreover, this project was fast: with Robin in hand, the entire project took about 10 weeks, which is way shorter than it would have taken if we had been doing all of the in-silico components ourselves. Important caveats: We are real biologists at FutureHouse, so I want to be clear that although the discovery here is exciting, we are not claiming that we have cured dry AMD. Fully validating this hypothesis as a treatment for dry AMD will take human trials, which will take much longer. Also, this discovery is cool, but it is not yet a "move 37"-style discovery. At the current rate of progress, I'm sure we will get to that level soon. Congratulations to the team. Congratulations in particular to Robin, which generated the hypotheses, proposed the experiments, analyzed the data and generated the figures. And major congratulations also to the human team, which built Robin: Michaela Hinks, Ali Ghareeb, Benjamin Chang, Ludovico Mitchener, Mo Razzak, Kiki Szostkiewicz, and Angela Yiu.

Sam Rodriques

1,107,754 Aufrufe • vor 1 Jahr

What does the reputation model look like for agents? (alpha leak below) And how do we associate the proofs that we have about human beings with the agents who represent them? You may have heard of a process called KYC or Know Your Customer. That's very common with traditional financial applications and services. We have introduced a concept that we call KYA or Know Your Agent, which is a structured way to be able to express what model, how data was used in training, who the deployer is, what entities this agent instance is accountable back to, providing not only provenance but identity of the associated organization or entity. That's also another root of trust that we think about a lot: Enterprises and organizations tied back to things like their domains. To share a little bit of an alpha leak here, a product that we're excited to be rolling out in the next few weeks will allow our enterprise partners to more easily verify and prove the traits and capabilities of their teams as well as their counterparties. On the agent front, that makes it really easy to prove that an agent is acting on behalf of a given business or entity. We've already seen lawsuits where the absence of such technology has been a huge risk, such as with airlines that incorporate ChatGPT wrappers in their support pages. And then those AI enabled interactions end up making up plane tickets that don't exist and those airlines have to honor them. As small of an example as that might be, being able to prove agent accountability also unlocks a huge set of opportunities for use in enterprise for those agent to agent interactions. The Deep Trust Framework that our team has put together that we're excited to be bringing into a friendly SDK form in the next few weeks for some of our partners includes those reputation based capabilities, so how you can basically keep track of the interactions an agent has had, associate all of that to the entity to which they're accountable, and then that creates a sustainable reputation model for these agent to agent Interactions. Source: Billions CEO Evin McMullen evin speaking at House of Chimera Spaces Event Dec 3, 2025

Billions Network

68,503 Aufrufe • vor 8 Monaten